These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 22186794)

  • 1. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.
    Parato KA; Breitbach CJ; Le Boeuf F; Wang J; Storbeck C; Ilkow C; Diallo JS; Falls T; Burns J; Garcia V; Kanji F; Evgin L; Hu K; Paradis F; Knowles S; Hwang TH; Vanderhyden BC; Auer R; Kirn DH; Bell JC
    Mol Ther; 2012 Apr; 20(4):749-58. PubMed ID: 22186794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.
    Thorne SH; Hwang TH; O'Gorman WE; Bartlett DL; Sei S; Kanji F; Brown C; Werier J; Cho JH; Lee DE; Wang Y; Bell J; Kirn DH
    J Clin Invest; 2007 Nov; 117(11):3350-8. PubMed ID: 17965776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.
    Lee JH; Roh MS; Lee YK; Kim MK; Han JY; Park BH; Trown P; Kirn DH; Hwang TH
    Cancer Gene Ther; 2010 Feb; 17(2):73-9. PubMed ID: 19629143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.
    Breitbach CJ; Thorne SH; Bell JC; Kirn DH
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1768-72. PubMed ID: 21740365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma.
    Hwang TH; Moon A; Burke J; Ribas A; Stephenson J; Breitbach CJ; Daneshmand M; De Silva N; Parato K; Diallo JS; Lee YS; Liu TC; Bell JC; Kirn DH
    Mol Ther; 2011 Oct; 19(10):1913-22. PubMed ID: 21772252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
    Park BH; Hwang T; Liu TC; Sze DY; Kim JS; Kwon HC; Oh SY; Han SY; Yoon JH; Hong SH; Moon A; Speth K; Park C; Ahn YJ; Daneshmand M; Rhee BG; Pinedo HM; Bell JC; Kirn DH
    Lancet Oncol; 2008 Jun; 9(6):533-42. PubMed ID: 18495536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.
    Breitbach CJ; Burke J; Jonker D; Stephenson J; Haas AR; Chow LQ; Nieva J; Hwang TH; Moon A; Patt R; Pelusio A; Le Boeuf F; Burns J; Evgin L; De Silva N; Cvancic S; Robertson T; Je JE; Lee YS; Parato K; Diallo JS; Fenster A; Daneshmand M; Bell JC; Kirn DH
    Nature; 2011 Aug; 477(7362):99-102. PubMed ID: 21886163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.
    Kim JH; Oh JY; Park BH; Lee DE; Kim JS; Park HE; Roh MS; Je JE; Yoon JH; Thorne SH; Kirn D; Hwang TH
    Mol Ther; 2006 Sep; 14(3):361-70. PubMed ID: 16905462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.
    Breitbach CJ; Arulanandam R; De Silva N; Thorne SH; Patt R; Daneshmand M; Moon A; Ilkow C; Burke J; Hwang TH; Heo J; Cho M; Chen H; Angarita FA; Addison C; McCart JA; Bell JC; Kirn DH
    Cancer Res; 2013 Feb; 73(4):1265-75. PubMed ID: 23393196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.
    Kirn DH; Wang Y; Le Boeuf F; Bell J; Thorne SH
    PLoS Med; 2007 Dec; 4(12):e353. PubMed ID: 18162040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.
    Heo J; Breitbach CJ; Moon A; Kim CW; Patt R; Kim MK; Lee YK; Oh SY; Woo HY; Parato K; Rintoul J; Falls T; Hickman T; Rhee BG; Bell JC; Kirn DH; Hwang TH
    Mol Ther; 2011 Jun; 19(6):1170-9. PubMed ID: 21427706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
    Deng L; Fan J; Guo M; Huang B
    Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma.
    Liu TC; Hwang T; Park BH; Bell J; Kirn DH
    Mol Ther; 2008 Sep; 16(9):1637-42. PubMed ID: 18628758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JX-594, a targeted oncolytic poxvirus for the treatment of cancer.
    Merrick AE; Ilett EJ; Melcher AA
    Curr Opin Investig Drugs; 2009 Dec; 10(12):1372-82. PubMed ID: 19943208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.
    Kirn DH; Thorne SH
    Nat Rev Cancer; 2009 Jan; 9(1):64-71. PubMed ID: 19104515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.
    Lun X; Chan J; Zhou H; Sun B; Kelly JJ; Stechishin OO; Bell JC; Parato K; Hu K; Vaillant D; Wang J; Liu TC; Breitbach C; Kirn D; Senger DL; Forsyth PA
    Mol Ther; 2010 Nov; 18(11):1927-36. PubMed ID: 20808290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.
    Heo J; Reid T; Ruo L; Breitbach CJ; Rose S; Bloomston M; Cho M; Lim HY; Chung HC; Kim CW; Burke J; Lencioni R; Hickman T; Moon A; Lee YS; Kim MK; Daneshmand M; Dubois K; Longpre L; Ngo M; Rooney C; Bell JC; Rhee BG; Patt R; Hwang TH; Kirn DH
    Nat Med; 2013 Mar; 19(3):329-36. PubMed ID: 23396206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trail armed oncolytic poxvirus suppresses lung cancer cell by inducing apoptosis.
    Hu J; Wang H; Gu J; Liu X; Zhou X
    Acta Biochim Biophys Sin (Shanghai); 2018 Oct; 50(10):1018-1027. PubMed ID: 30137199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation.
    Liu Z; Yang Y; Zhang X; Wang H; Xu W; Wang H; Xiao F; Bai Z; Yao H; Ma X; Jin L; Wu C; Seth P; Zhang Z; Wang L
    Hum Gene Ther; 2017 Aug; 28(8):667-680. PubMed ID: 28530155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.